The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

Paul Di Cesare,MD

Status and phase: Completed; Phase 4

Conditions: Total Knee Replacement

Treatments: Drug: Fondaparinux Sodium (Arixtra)

Study type: Interventional

Funder types: Other

Identifiers

NCT00909064

200816251

GSK576428

Details and patient eligibility

About

The investigators hypothesize that Arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.

Enrollment: 114 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All primary unilateral TKA and THA cases will be included.

Exclusion criteria

• Patients less than 50 kg, Patients with CrCl<30ml/min. Revision and bilateral procedures will be excluded.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

114 participants in 1 patient group

Arixtra

Experimental group

Description:

Effect of Arixtra on would drainage and length of stay for the patients with hip and knee replacement

Treatment:

Drug: Fondaparinux Sodium (Arixtra)